[HTML][HTML] Epidemiology of community-acquired pneumonia in older adults: a population-based study
A Vila-Corcoles, O Ochoa-Gondar… - Respiratory …, 2009 - Elsevier
OBJECTIVE: This study assessed incidence, aetiology, clinical outcomes and risk factors for
community-acquired pneumonia (CAP) in older adults. METHODS: This was a population-…
community-acquired pneumonia (CAP) in older adults. METHODS: This was a population-…
Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study
A Vila-Córcoles, O Ochoa-Gondar… - Clinical infectious …, 2006 - academic.oup.com
Background . The 23-valent polysaccharide pneumococcal vaccine (PPV) is currently
recommended for elderly persons and persons who are at high risk of infection. However, the …
recommended for elderly persons and persons who are at high risk of infection. However, the …
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged≥ 60 years: 3 years of …
O Ochoa-Gondar, A Vila-Corcoles… - Clinical infectious …, 2014 - academic.oup.com
Background. The benefits of using the 23-valent pneumococcal polysaccharide vaccine (PPV23)
are controversial. This study assessed clinical effectiveness of PPV23 in preventing …
are controversial. This study assessed clinical effectiveness of PPV23 in preventing …
[HTML][HTML] The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study
O Ochoa-Gondar, A Vila-Córcoles, C de Diego, V Arija… - BMC public health, 2008 - Springer
Background Community-acquired pneumonia (CAP) is generally considered a major cause
of morbidity and mortality in the elderly. However, population-based data are very limited …
of morbidity and mortality in the elderly. However, population-based data are very limited …
Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case–control study
…, E Salsench, T Rodriguez-Blanco, O Ochoa-Gondar… - Vaccine, 2009 - Elsevier
The 23-valent polysaccharide pneumococcal vaccine is currently recommended in elderly
and high-risk adults. Its efficacy against invasive pneumococcal disease has been …
and high-risk adults. Its efficacy against invasive pneumococcal disease has been …
Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain
A Vila-Córcoles, O Ochoa-Gondar, EM Satué-Gracia… - BMJ open, 2020 - bmjopen.bmj.com
Objective To investigate possible relationships between pre-existing medical conditions (including
common comorbidities and chronic medications) and risk for suffering COVID-19 …
common comorbidities and chronic medications) and risk for suffering COVID-19 …
[HTML][HTML] Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice
A Vila-Corcoles, O Ochoa-Gondar - Drugs & aging, 2013 - Springer
Streptococcus pneumoniae remains a major cause of morbidity and mortality throughout the
world. To date, after the introduction of routine childhood immunization, elderly people (ie, …
world. To date, after the introduction of routine childhood immunization, elderly people (ie, …
Use of distinct anti‐hypertensive drugs and risk for COVID‐19 among hypertensive people: a population‐based cohort study in Southern Catalonia, Spain
…, E Satue‐Gracia, O Ochoa‐Gondar… - The Journal of …, 2020 - Wiley Online Library
The use of some anti‐hypertensive drugs in the current COVID‐19 pandemic has become
controversial. This study investigated possible relationships between anti‐hypertensive …
controversial. This study investigated possible relationships between anti‐hypertensive …
[HTML][HTML] COVID19-related and all-cause mortality risk among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection: a population …
…, I Hospital-Guardiola, O Ochoa-Gondar… - BMC Public Health, 2021 - Springer
Background Direct and indirect COVID19-related mortality is uncertain. This study investigated
all-cause and COVID19-related deaths among middle-aged and older adults during the …
all-cause and COVID19-related deaths among middle-aged and older adults during the …
[HTML][HTML] Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
A Vila-Corcoles, O Ochoa-Gondar, JA Guzmán… - BMC infectious …, 2010 - Springer
Background The 23-valent polysaccharide pneumococcal vaccine (PPV) is currently
recommended in elderly and high-risk adults. However, its efficacy in preventing pneumococcal …
recommended in elderly and high-risk adults. However, its efficacy in preventing pneumococcal …